Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, 2004 Mowry Road, Gainesville, FL, USA.
Division of Quantitative Sciences, University of Florida Health Cancer Center, Gainesville, USA.
J Gen Intern Med. 2021 Nov;36(11):3353-3360. doi: 10.1007/s11606-021-06615-w. Epub 2021 Feb 1.
Recent clinical trials suggest that e-cigarettes may be more effective for smoking cessation than traditional cessation aids, yet primary care physician (PCP) practices regarding e-cigarette recommendations for smokers have not been studied in-depth.
To identify factors influencing PCP recommendation of e-cigarettes for smoking cessation.
Discrete choice experiment and survey.
Florida PCPs.
The survey included a discrete choice experiment in which PCPs indicated whether they would recommend e-cigarettes for each of 8 hypothetical patient profiles with the following contrasting characteristics: e-cigarette use, interest in approved cessation methods, smoking intensity, prior experience with approved cessation medications, quit intention, age, and comorbidity. Responses were summarized using descriptive statistics and standardized scores (SS).
The sample (n = 216) was predominately male (76%), white (66%), and non-Hispanic (78%), and most respondents had held their medical degree for 20+ years (77%). The response rate was 28.7%. Most PCPs thought e-cigarettes were at least somewhat effective for smoking cessation (66%) and lowering disease risk (65%); 31% perceived e-cigarettes to be equally/more effective than traditional cessation aids. PCPs were split regarding whether e-cigarettes were less (50%) or equally harmful (38%) as cigarettes. Yet, few were very confident in their ability to counsel patients on e-cigarettes risks (27%) or benefits (15%). PCPs recommended e-cigarettes in 27% of patient profiles they evaluated. The most important factors influencing the decision to recommend or not recommend e-cigarette were patients' prior use of nicotine replacement therapy with (SS = 0.22, 95% CI = 0.17-0.27) and without use of other medications for cessation (SS = 0.18, 95% CI = 0.13-0.23), and being middle age (50 years old) with chronic obstructive pulmonary disease (SS = 0.16, 95% CI = 0.10-0.23).
Considering the increased patient use of e-cigarettes and increasing use for cessation, this study highlights the need for guidelines and education to aid PCPs' counseling of patients about e-cigarette use.
最近的临床试验表明,电子烟在戒烟方面可能比传统的戒烟辅助工具更有效,但初级保健医生(PCP)对电子烟戒烟推荐的实践尚未进行深入研究。
确定影响 PCP 推荐电子烟戒烟的因素。
离散选择实验和调查。
佛罗里达州的 PCP。
该调查包括一个离散选择实验,其中 PCP 表示他们是否会为 8 个具有以下对比特征的假设患者简介推荐电子烟:电子烟使用、对已批准的戒烟方法的兴趣、吸烟强度、以前使用已批准的戒烟药物的经验、戒烟意向、年龄和合并症。使用描述性统计和标准化分数(SS)总结响应。
样本(n=216)主要为男性(76%)、白人(66%)和非西班牙裔(78%),大多数受访者持有医学学位超过 20 年(77%)。回复率为 28.7%。大多数 PCP 认为电子烟对戒烟(66%)和降低疾病风险(65%)至少有一定效果;31%的人认为电子烟与传统戒烟辅助工具同样有效/更有效。对于电子烟是否比香烟危害更小(50%)或同样危害(38%),PCP 存在分歧。然而,很少有人对自己在电子烟风险(27%)或益处(15%)方面咨询患者的能力非常有信心。PCP 在他们评估的 27%的患者简介中推荐电子烟。影响推荐或不推荐电子烟决定的最重要因素是患者之前是否使用尼古丁替代疗法(SS=0.22,95%CI=0.17-0.27)和是否使用其他药物戒烟(SS=0.18,95%CI=0.13-0.23),以及年龄在 50 岁左右(SS=0.16,95%CI=0.10-0.23),患有慢性阻塞性肺疾病。
考虑到患者越来越多地使用电子烟以及电子烟在戒烟方面的使用增加,本研究强调需要指南和教育来帮助 PCP 为患者提供电子烟使用方面的咨询。